Management and Treatment Outcomes of Patients Enrolled in MDR-TB Treatment in Viet Nam

Overview

Journal Public Health Action

Date 2016 Apr 7

PMID 27051608

Citations 12

Authors

N T M Phuong

N V Nhung

N B Hoa

H T Thuy

K C Takarinda

K Tayler-Smith

A D Harries

Affiliations

Soon will be listed here.

Abstract

Setting: The programmatic management of drug-resistant tuberculosis (TB) in Viet Nam has been rapidly scaled up since 2009.

Objectives: To document the annual numbers of patients enrolled for multidrug-resistant tuberculosis (MDR-TB) treatment during 2010-2014 and to determine characteristics and treatment outcomes of patients initiating treatment during 2010-2012.

Design: A retrospective cohort study using national reports and data from the national electronic data system for drug-resistant TB.

Results: The number of patients enrolled annually for MDR-TB treatment increased from 97 in 2010 to 1522 in 2014. The majority of patients were middle-aged men who had pulmonary disease and had failed a retreatment regimen; 77% had received ⩾2 courses of TB treatment. Favourable outcomes (cured and treatment completed) were attained in 73% of patients. Unfavourable outcomes included loss to follow-up (12.5%), death (8%) and failure (6.3%). Having had ⩾2 previous treatment courses and being human immunodeficiency virus-positive were associated with unfavourable outcomes.

Conclusion: Increasing numbers of patients are being treated for MDR-TB each year with good treatment outcomes under national programme management in Viet Nam. However, there is a need to increase case detection-currently at 30% of the estimated 5100 MDR-TB cases per year, reduce adverse outcomes and improve monitoring and evaluation.

Citing Articles

Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis.

Koroma J, Elduma A, Sesay U, Gebru G BMC Infect Dis. 2024; 24(1):579.

PMID: 38862873 PMC: 11167780. DOI: 10.1186/s12879-024-09370-5.

Determinants of catastrophic costs among households affected by multi-drug resistant tuberculosis in Ho Chi Minh City, Viet Nam: a prospective cohort study.

Pham T, Forse R, Codlin A, Phan T, Nguyen T, Nguyen N BMC Public Health. 2023; 23(1):2372.

PMID: 38042797 PMC: 10693707. DOI: 10.1186/s12889-023-17078-5.

Development and Validation of a Nomogram for the Prediction of Unfavorable Treatment Outcome Among Multi-Drug Resistant Tuberculosis Patients in North West Ethiopia: An Application of Prediction Modelling.

Anley D, Akalu T, Merid M, Tsegaye T Infect Drug Resist. 2022; 15:3887-3904.

PMID: 35903578 PMC: 9317379. DOI: 10.2147/IDR.S372351.

Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: a retrospective cohort study.

Wrohan I, Nguyen T, Nguyen V, Nguyen B, Hoang T, Nguyen P BMC Infect Dis. 2022; 22(1):68.

PMID: 35057754 PMC: 8772201. DOI: 10.1186/s12879-021-06992-x.

Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda.

Kasozi S, Kirirabwa N, Kimuli D, Luwaga H, Kizito E, Turyahabwe S PLoS One. 2020; 15(12):e0244451.

PMID: 33373997 PMC: 7772013. DOI: 10.1371/journal.pone.0244451.

References

Brust J, Gandhi N, Carrara H, Osburn G, Padayatchi N . High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010; 14(4):413-9. PMC: 3005763. View

Gandhi N, Shah N, Andrews J, Vella V, Moll A, Scott M . HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2009; 181(1):80-6. DOI: 10.1164/rccm.200907-0989OC. View

Hoang T, Nguyen N, Dinh S, Nguyen H, Cobelens F, Thwaites G . Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam. BMC Public Health. 2015; 15:980. PMC: 4587724. DOI: 10.1186/s12889-015-2338-5. View

Tharu M, Harries A, Goel S, Srivastava S, Kumar A, Adhikari M . Screening retreatment tuberculosis patients for drug resistance in mid-west Nepal: how well are we doing?. Public Health Action. 2015; 4(1):60-5. PMC: 4479092. DOI: 10.5588/pha.13.0104. View

Hoa N, Sy D, Nhung N, Tiemersma E, Borgdorff M, Cobelens F . National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010; 88(4):273-80. PMC: 2855599. DOI: 10.2471/BLT.09.067801. View

Harries A, Michongwe J, Nyirenda T, Kemp J, Squire S, Ramsay A . Using a bus service for transporting sputum specimens to the Central Reference Laboratory: effect on the routine TB culture service in Malawi. Int J Tuberc Lung Dis. 2004; 8(2):204-10. View

Edginton M, Enarson D, Zachariah R, Reid T, Satyanarayana S, Bissell K . Why ethics is indispensable for good-quality operational research. Public Health Action. 2015; 2(1):21-2. PMC: 4536562. DOI: 10.5588/pha.12.0001. View

Van Deun A, Maug A, Salim M, Das P, Sarker M, Daru P . Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182(5):684-92. DOI: 10.1164/rccm.201001-0077OC. View

Palacios E, Franke M, Munoz M, Hurtado R, Dallman R, Chalco K . HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis. 2012; 16(3):348-54. DOI: 10.5588/ijtld.11.0473. View

10.

Islam T, Marais B, Nhung N, Chiang C, Yew W, Yoshiyama T . Western Pacific Regional Green Light Committee: progress and way forward. Int J Infect Dis. 2015; 32:161-5. PMC: 5384424. DOI: 10.1016/j.ijid.2015.01.001. View

11.

Aung K, Van Deun A, Declercq E, Sarker M, Das P, Hossain M . Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014; 18(10):1180-7. DOI: 10.5588/ijtld.14.0100. View

12.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007; 85(11):867-72. PMC: 2636253. DOI: 10.2471/blt.07.045120. View

13.

Mor Z, Goldblatt D, Kaidar-Shwartz H, Cedar N, Rorman E, Chemtob D . Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes. Int J Tuberc Lung Dis. 2014; 18(10):1195-201. DOI: 10.5588/ijtld.14.0192. View

14.

Chadha S, Sharath B, Reddy K, Jaju J, Vishnu P, Rao S . Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLoS One. 2011; 6(11):e26659. PMC: 3206824. DOI: 10.1371/journal.pone.0026659. View

15.

Nhung N, Hoa N, Sy D, Hennig C, Dean A . The fourth national anti-tuberculosis drug resistance survey in Viet Nam. Int J Tuberc Lung Dis. 2015; 19(6):670-5. DOI: 10.5588/ijtld.14.0785. View

16.

Hoa N, Khanh P, Chinh N, Hennig C . Prescription patterns and treatment outcomes of MDR-TB patients treated within and outside the National Tuberculosis Programme in Pham Ngoc Thach hospital, Viet Nam. Trop Med Int Health. 2014; 19(9):1076-81. DOI: 10.1111/tmi.12347. View

17.

Rodriguez M, Monedero I, Caminero J, Encarnacion M, Dominguez Y, Acosta I . Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013; 17(4):520-5. DOI: 10.5588/ijtld.12.0481. View